CD274 and neoplasm: In the monotherapy validation cohort, IRS-H patients not indicated for anti-PD-(L)1 treatment (whether by tumor type, MSI-H or TMB-H) are poorly represented, as would be expected from a real-world cohort where IRS status was not provided to guide treatment.